Ovintiv Inc. (OVV)

Ovintiv's shares fell 5.61% in the first session after its November 3, 2026 report, when adjusted EPS of $1.95 came in 2.50% below the $2.00 analyst estimate. The stock has since recovered to $63.47, up 3.04% in the last session, but it still trades 1.75% below its 50-day average of $64.60 while holding 8.43% above its 200-day average of $58.54. Wall Street remains constructive: 21 of 25 analysts rate the stock Buy or Strong Buy, and the median target of $80.00 sits 26.0% above the current price. CleaRank rates the stock Buy with a score of 66/100, driven mainly by valuation and analyst support, with momentum the main drag.

Ovintiv reported adjusted EPS of $1.95 on November 3, 2026, which was 2.50% below the analysts' estimate of $2.00, and the stock fell 5.61% in the first session that followed. The miss was the second in the last three reports after a July 23, 2026 shortfall of 10.31% led to a 2.83% gain. Over the six most recent reports, three were beats and two were misses, and the share price was lower in the first session after four of the six. The reaction suggests the market is paying more attention to the quality of the result than to the headline beat rate.

At a trailing P/E of 12.67, the stock trades at a discount to the sector median P/E of 18.4, 31.1% below it. The price-to-sales ratio of 1.70 is also below the sector median of 2.5, a gap of 30.0%. Trailing GAAP earnings of $5.01 per share support that multiple. Profitability is mixed: the net profit margin is 13.1% and return on equity is 12.10%, below the sector median of 14.2%, while the operating margin of 34.32% is strong and debt-to-equity is a moderate 0.44.

Revenue grew 29.98% in the latest quarter compared with the same quarter a year earlier, but that is slower than the sector median of 32.8%, a gap of 2.8 percentage points. Analysts expect EPS to grow 70.8% this fiscal year to $8.27 and revenue to grow 15.7% to $10.3B. Next year's EPS growth is expected to slow to 4.8%, reaching $8.67. Of 25 analysts, 21 rate the stock Buy or Strong Buy, 4 Hold, and none Sell. Truist Securities and Wells Fargo kept their ratings on November 5, 2026, and Barclays and Evercore ISI Group did the same on November 4, 2026.

The price sits 8.43% above the 200-day average and 1.75% below the 50-day average, a mixed picture that leaves the medium-term trend intact but unconfirmed. The 50-day average is 10.36% above the 200-day average. The 14-day RSI of 44.3 is in the neutral zone, and the MACD line is negative, which keeps momentum a drag on the overall picture. Insiders sold $5.9M of stock over the last 18 months across 7 sales and made no open-market purchases.

The base case is that OVV trades in a range between its 200-day average and its 50-day average while the market weighs a earnings miss against strong analyst backing. Analysts' median target of $80.00 and a high of $97.00 assume that stronger earnings delivery continues; the lowest target of $65.00 sits only slightly above the current price. The analysts' EPS estimate of $8.27 for this fiscal year implies strong expected growth, but that figure has not yet been matched by the reported quarters, so execution in the coming reports matters most.

Support sits first at the 200-day simple moving average of $58.54, the nearest level below the price; a fall to it would test the longer-term uptrend that the stock has held since the spring. The second support is the 52-week low of $36.81, a far-off floor that would only be reached in a sharp sell-off. Resistance comes first at the 50-day simple moving average of $64.60, which the price has just sat under, followed by the 20-day exponential moving average at $65.30. The third level above the price is the 52-week high of $73.62, which would require a sustained move higher to reach.